Related Experiment Videos
[Phase I-II study of recombinant interferon gamma]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|June 1, 1985
Summary
Human recombinant interferon gamma (rIFN-gamma) showed reversible toxicities in advanced cancer patients. While no complete responses were observed, stable disease occurred in some patients, warranting further investigation.
Area of Science:
- Oncology
- Immunotherapy
- Pharmacology
Context:
- Investigating novel treatments for advanced cancers refractory to standard chemotherapy.
- Evaluating the safety and efficacy of human recombinant interferon gamma (rIFN-gamma).
Purpose:
- To assess the dose-escalation safety and pharmacokinetics of rIFN-gamma in cancer patients.
- To explore the preliminary efficacy of rIFN-gamma in a phase II setting.
Summary:
- Phase I/II study involving escalating doses of rIFN-gamma via intravenous infusion.
- Identified dose-related toxicities including fever, leukopenia, and fatigue, which were reversible.
- Selected a dose of 6 X 10(6) U/m2 intramuscularly for phase II; observed stable disease in renal cell, breast, and ovarian cancers without tachyphylaxis.
Impact:
- Established tolerable dosing and identified key toxicities for rIFN-gamma therapy.
- Provided preliminary data on stable disease in specific advanced cancers.
- Highlighted the need for further studies with higher doses to evaluate antitumor effects.